A visual simulator (SimVisGekko, 2EyesVision) helps patients to choose how well multifocal IOLs function before surgical implantation and improve satisfaction with surgical outcomes.
A visual simulator (SimVisGekko, 2EyesVision) that provides patients the experience of vision with multifocal IOLs (mIOLs) before actual implantation may help to manage patient expectations, according to Susana Marcos, PhD.
This innovation arose out of the scaling down of technologies that originated in astronomy, i.e., adaptive optics, into a system useful to ophthalmologists for prescribing correction for presbyopia and simulating mIOLs.
Despite the availability of mIOLs, only 7% of patients opt for this correction modality after cataract surgery, noted Dr. Marcos, research professor, Instituto de Optica Daza de Valdés, Consejo Superior de Investigaciones Científicas, Madrid.
The challenge may be the difficulty with explaining multifocality to patients.
In addition, it is difficult for patients to decide about mIOL implantation if they cannot visualize what their vision will be preoperatively, a scenario that leaves them with uncertainty about both their expectations and the actual surgical results.
A solution to this may be use of the mobile visual simulator that would ease their decision-making process.
“Visual simulators will help to sell more premium lenses and screen out prospective unhappy patients,” Dr. Marcos said. “This technology would be valuable for patients, clinicians, and IOL manufacturers.”
The device provides practical utility in the clinic, in that it improves patient satisfaction, facilitates comparison of corrective solutions, and saves time by providing an easy explanation of multifocality. It also provides business advantages by reducing patient complaints and refunds, provides a competitive advantage to doctors who adopt the device early, and increases the number of mIOL prescriptions.
Susana Marcos, PhD
E: [email protected]
Dr. Marcos is coinventor of the SimVis technology and co-founder and shareholder in 2EyesVision.